###begin article-title 0
###xml 21 26 21 26 <italic>hMLH1</italic>
The G67E mutation in hMLH1 is associated with an unusual presentation of Lynch syndrome
###end article-title 0
###begin p 1
These authors contributed equally to this work
###end p 1
###begin p 2
This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.
###end p 2
###begin p 3
###xml 200 205 200 205 <italic>hMLH1</italic>
###xml 325 329 325 329 <italic>G67E</italic>
###xml 357 373 357 373 <italic>hMLH1-p.Gly67Arg</italic>
###xml 436 450 436 450 <italic>hMLH1-Gly67Arg</italic>
###xml 516 521 516 521 <italic>et al</italic>
###xml 505 527 505 527 <xref ref-type="other" rid="bib35">Shimodaira <italic>et al</italic>, 1998</xref>
###xml 799 813 799 813 <italic>yMLH1-Gly64Glu</italic>
###xml 870 884 870 884 <italic>yMLH1-Gly64Arg</italic>
###xml 974 989 974 989 <italic>hMLH1-Gly67Glu,</italic>
###xml 1105 1119 1105 1119 <italic>hMLH1-Gly67Arg</italic>
###xml 1260 1265 1260 1265 <italic>hMLH1</italic>
###xml 727 732 <span type="species:ncbi:4932">yeast</span>
Germline mutations in the mismatch repair (MMR) genes are associated with Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Here, we characterise a variant of hMLH1 that confers a loss-of-function MMR phenotype. The mutation changes the highly conserved Gly67 residue to a glutamate (G67E) and is reminiscent of the hMLH1-p.Gly67Arg mutation, which is present in several Lynch syndrome cohorts. hMLH1-Gly67Arg has previously been shown to confer loss-of-function (Shimodaira et al, 1998), and two functional assays suggest that the hMLH1-Gly67Glu protein fails to sustain normal MMR functions. In the first assay, hMLH1-Gly67Glu abolishes the protein's ability to interfere with MMR in yeast. In the second assay, mutation of the analogous residue in yMLH1 (yMLH1-Gly64Glu) causes a loss-of-function mutator phenotype similar to yMLH1-Gly64Arg. Despite these molecular similarities, an unusual spectrum of tumours is associated with hMLH1-Gly67Glu, which is not typical of those associated with Lynch syndrome and differs from those found in families carrying the hMLH1-Gly67Arg allele. This suggests that hMLH1 may have different functions in certain tissues and/or that additional factors may modify the influence of hMLH1 mutations in causing Lynch syndrome.
###end p 3
###begin p 4
###xml 412 442 412 442 <xref ref-type="other" rid="bib21">Lynch and de la Chapelle, 2003</xref>
###xml 744 749 744 749 <italic>et al</italic>
###xml 738 755 738 755 <xref ref-type="other" rid="bib42">Vasen <italic>et al</italic>, 1999</xref>
###xml 762 767 762 767 <italic>et al</italic>
###xml 757 773 757 773 <xref ref-type="other" rid="bib41">Umar <italic>et al</italic>, 2004</xref>
Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is an autosomal dominant cancer predisposition disorder. Apart from colorectal cancers, affected individuals are also predisposed to an array or other cancers, such as endometrial cancer, transitional cell carcinomas of the upper urothelial tract, carcinoma of the stomach, hepatobiliary and small intestinal cancers (reviewed in Lynch and de la Chapelle, 2003). Sets of criteria that trigger investigation of the possibility of a Lynch syndrome diagnosis include the revised Bethesda and the Amsterdam I and II criteria, which consider the combinations of tumours in individuals and families, the age of tumour onset and pathological features of tumours (Vasen et al, 1999; Umar et al, 2004).
###end p 4
###begin p 5
###xml 112 117 112 117 <italic>et al</italic>
###xml 105 123 105 123 <xref ref-type="other" rid="bib8">Fishel <italic>et al</italic>, 1993</xref>
###xml 133 138 133 138 <italic>et al</italic>
###xml 125 144 125 144 <xref ref-type="other" rid="bib6">Bronner <italic>et al</italic>, 1994</xref>
###xml 157 162 157 162 <italic>et al</italic>
###xml 146 168 146 168 <xref ref-type="other" rid="bib25">Nicolaides <italic>et al</italic>, 1994</xref>
###xml 183 188 183 188 <italic>et al</italic>
###xml 170 194 170 194 <xref ref-type="other" rid="bib27">Papadopoulos <italic>et al</italic>, 1994</xref>
###xml 196 204 196 204 <xref ref-type="other" rid="bib20">Li, 2003</xref>
###xml 770 775 770 775 <italic>MRE11</italic>
###xml 777 782 777 782 <italic>RAD50</italic>
###xml 787 792 787 792 <italic>BRCA1</italic>
###xml 815 819 815 819 <italic>CHK1</italic>
###xml 831 836 831 836 <italic>et al</italic>
###xml 821 842 821 842 <xref ref-type="other" rid="bib43">Yoshikawa <italic>et al</italic>, 2000</xref>
###xml 851 856 851 856 <italic>et al</italic>
###xml 844 862 844 862 <xref ref-type="other" rid="bib23">Menoyo <italic>et al</italic>, 2001</xref>
###xml 873 878 873 878 <italic>et al</italic>
###xml 864 884 864 884 <xref ref-type="other" rid="bib9">Giannini <italic>et al</italic>, 2002</xref>
###xml 890 895 890 895 <italic>et al</italic>
###xml 886 901 886 901 <xref ref-type="other" rid="bib17">Kim <italic>et al</italic>, 2007</xref>
###xml 914 924 914 921 <italic>TGF&#946;-R2</italic>
###xml 926 935 923 932 <italic>PTEN, APC</italic>
###xml 940 944 937 941 <italic>MBD4</italic>
###xml 956 961 953 958 <italic>et al</italic>
###xml 946 967 943 964 <xref ref-type="other" rid="bib22">Markowitz <italic>et al</italic>, 1995</xref>
###xml 975 980 972 977 <italic>et al</italic>
###xml 969 986 966 983 <xref ref-type="other" rid="bib14">Huang <italic>et al</italic>, 1996</xref>
###xml 993 998 990 995 <italic>et al</italic>
###xml 988 1004 985 1001 <xref ref-type="other" rid="bib18">Kong <italic>et al</italic>, 1997</xref>
###xml 1014 1019 1011 1016 <italic>et al</italic>
###xml 1006 1025 1003 1022 <xref ref-type="other" rid="bib37">Tashiro <italic>et al</italic>, 1997</xref>
###xml 1034 1039 1031 1036 <italic>et al</italic>
###xml 1027 1045 1024 1042 <xref ref-type="other" rid="bib32">Riccio <italic>et al</italic>, 1999</xref>
###xml 447 452 <span type="species:ncbi:9606">human</span>
In the 1990s, a number of studies linked Lynch syndrome to mutations in the mismatch repair (MMR) genes (Fishel et al, 1993; Bronner et al, 1994; Nicolaides et al, 1994; Papadopoulos et al, 1994; Li, 2003). The MMR proteins prevent the accumulation of DNA replication errors by detecting and effecting the removal of base-base mismatches as well as small insertion-deletion loops from the newly synthesised strand. Tissue samples from tumours and human cell lines in which MMR has been inactivated show variation in the length of repetitive DNA sequences (microsatellites), a phenomenon known as microsatellite instability (MSI). These include mononucleotide repeats of adenine, which are often mutated in MMR-defective cells, and are present in DNA damage repair genes MRE11, RAD50 and BRCA1, checkpoint component CHK1 (Yoshikawa et al, 2000; Menoyo et al, 2001; Giannini et al, 2002; Kim et al, 2007) as well as TGFbeta-R2, PTEN, APC and MBD4 (Markowitz et al, 1995; Huang et al, 1996; Kong et al, 1997; Tashiro et al, 1997; Riccio et al, 1999).
###end p 5
###begin p 6
###xml 75 88 75 88 <xref ref-type="other" rid="bib24">Modrich, 2006</xref>
###xml 137 142 137 138 <italic>&#945;</italic>
###xml 163 167 159 160 <italic>&#946;</italic>
###xml 271 276 264 265 <italic>&#945;</italic>
###xml 322 326 311 312 <italic>&#946;</italic>
###xml 483 488 469 474 <italic>et al</italic>
###xml 475 494 461 480 <xref ref-type="other" rid="bib15">Kadyrov <italic>et al</italic>, 2006</xref>
###xml 497 505 483 491 <italic>In vitro</italic>
###xml 543 548 529 530 <italic>&#945;</italic>
###xml 663 668 645 650 <italic>et al</italic>
###xml 654 674 636 656 <xref ref-type="other" rid="bib7">Dzantiev <italic>et al</italic>, 2004</xref>
###xml 68 73 <span type="species:ncbi:9606">human</span>
Components of the MMR pathway are highly conserved from bacteria to human (Modrich, 2006). In eukaryotes, heterodimers of MSH2-MSH6 (MutSalpha) and MSH2-MSH3 (MutSbeta) detect mismatches and insertion-deletion loops and form complexes with heterodimers of MLH1-PMS2 (MutLalpha), and to a lesser extent with MLH1-MLH3 (MutLbeta). hPMS2 contains endonuclease activity that can initiate the removal of the newly synthesised strand, which contains the incorrectly inserted base (Kadyrov et al, 2006). In vitro reconstitution of MMR shows that MutLalpha is required for 3'-directed excision of the mismatch, in addition to factors such as PCNA, RPA and EXOI (Dzantiev et al, 2004).
###end p 6
###begin p 7
###xml 122 127 122 127 <italic>hMSH2</italic>
###xml 131 136 131 136 <italic>hMLH1</italic>
More than 450 germline abnormalities of MMR genes have been described (InSiGHT, ). Whether a specific missense variant in hMSH2 or hMLH1 confers pathogenicity can be difficult to determine, as it requires the evaluation of multiple parameters, including statistical analyses of the segregation of the variant with the phenotype and functional assessment of the variant protein. Segregation of the variant within a family may provide some evidence, but this could in theory be caused by another closely linked mutation. Small family size, incomplete penetrance of mutations and lack of confirmatory records on tumours from older generations can often limit the power of such analyses. Collation of data on variants from different families is helpful, but is not available if variants are rare or novel.
###end p 7
###begin p 8
###xml 227 231 227 231 <italic>MLH1</italic>
###xml 316 321 316 321 <italic>et al</italic>
###xml 308 327 308 327 <xref ref-type="other" rid="bib5">Brieger <italic>et al</italic>, 2002</xref>
###xml 336 341 336 341 <italic>et al</italic>
###xml 329 347 329 347 <xref ref-type="other" rid="bib40">Trojan <italic>et al</italic>, 2002</xref>
###xml 355 360 355 360 <italic>et al</italic>
###xml 349 366 349 366 <xref ref-type="other" rid="bib4">Blasi <italic>et al</italic>, 2006</xref>
###xml 513 518 513 518 <italic>et al</italic>
###xml 499 524 499 524 <xref ref-type="other" rid="bib26">Nystrom-Lahti <italic>et al</italic>, 2002</xref>
###xml 542 550 542 550 <italic>in vitro</italic>
###xml 762 767 762 767 <italic>et al</italic>
###xml 748 773 748 773 <xref ref-type="other" rid="bib26">Nystrom-Lahti <italic>et al</italic>, 2002</xref>
###xml 782 787 782 787 <italic>et al</italic>
###xml 775 793 775 793 <xref ref-type="other" rid="bib10">Heinen <italic>et al</italic>, 2002</xref>
###xml 820 828 820 828 <italic>in vitro</italic>
###xml 1018 1023 1018 1023 <italic>et al</italic>
###xml 1010 1029 1010 1029 <xref ref-type="other" rid="bib16">Kariola <italic>et al</italic>, 2002</xref>
###xml 1437 1442 1437 1442 <italic>et al</italic>
###xml 1426 1448 1426 1448 <xref ref-type="other" rid="bib35">Shimodaira <italic>et al</italic>, 1998</xref>
###xml 1460 1465 1460 1465 <italic>et al</italic>
###xml 1450 1471 1450 1471 <xref ref-type="other" rid="bib30">Quaresima <italic>et al</italic>, 2003</xref>
###xml 1495 1500 1495 1500 <italic>hMLH1</italic>
###xml 1529 1534 1529 1534 <italic>hMLH1</italic>
###xml 1621 1626 1621 1626 <italic>et al</italic>
###xml 1610 1632 1610 1632 <xref ref-type="other" rid="bib35">Shimodaira <italic>et al</italic>, 1998</xref>
###xml 1644 1649 1644 1649 <italic>et al</italic>
###xml 1634 1655 1634 1655 <xref ref-type="other" rid="bib30">Quaresima <italic>et al</italic>, 2003</xref>
###xml 1667 1672 1667 1672 <italic>et al</italic>
###xml 1657 1678 1657 1678 <xref ref-type="other" rid="bib36">Takahashi <italic>et al</italic>, 2007</xref>
###xml 1692 1700 1692 1700 <italic>in vitro</italic>
###xml 1756 1761 1756 1761 <italic>et al</italic>
###xml 1746 1767 1746 1767 <xref ref-type="other" rid="bib36">Takahashi <italic>et al</italic>, 2007</xref>
###xml 1844 1849 1844 1849 <italic>hMLH1</italic>
###xml 1964 1969 1964 1969 <italic>hMLH1</italic>
###xml 2002 2007 2002 2007 <italic>yMLH1</italic>
###xml 2009 2038 2009 2038 <xref ref-type="other" rid="bib34">Shcherbakova and Kunkel, 1999</xref>
###xml 2049 2054 2049 2054 <italic>et al</italic>
###xml 2040 2060 2040 2060 <xref ref-type="other" rid="bib13">Hoffmann <italic>et al</italic>, 2003</xref>
###xml 2161 2165 2161 2165 <italic>MLH1</italic>
###xml 2212 2217 2212 2217 <italic>hMLH1</italic>
###xml 2254 2259 2254 2259 <italic>et al</italic>
###xml 2245 2265 2245 2265 <xref ref-type="other" rid="bib29">Polaczek <italic>et al</italic>, 1998</xref>
###xml 1202 1207 <span type="species:ncbi:4932">yeast</span>
###xml 1316 1321 <span type="species:ncbi:4932">yeast</span>
###xml 1862 1867 <span type="species:ncbi:4932">yeast</span>
###xml 2155 2160 <span type="species:ncbi:4932">yeast</span>
###xml 2238 2243 <span type="species:ncbi:4932">yeast</span>
There are several functional tests available to assess variant protein activity, although they each have their limitations. Mismatch repair-deficient tumour-derived cell lines can be transfected with plasmid containing variant MLH1 genes and assessed for mutator phenotype and/or drug-resistance phenotypes (Brieger et al, 2002; Trojan et al, 2002; Blasi et al, 2006). For C-terminal mutations in hMLH1 and hPMS2, testing the variant proteins for interactions with their partner can be informative (Nystrom-Lahti et al, 2002). There are also in vitro tests for MMR activity, which rely upon the complementation of MMR-deficient extracts by the variant protein. However, these assays require expression and purification of recombinant MMR proteins (Nystrom-Lahti et al, 2002; Heinen et al, 2002), and although MMR repair in vitro may be deemed normal when sufficient quantities of the variant protein is used, some variants are poorly expressed, suggesting that the cellular levels of the variant may be lower (Kariola et al, 2002). All of these assays require tissue culture facilities and/or recombinant protein expression, significant skill, and can be costly. To overcome these limitations, several yeast and bacteria-based systems for the functional analysis of variant MMR proteins have been developed. In both yeast and bacteria, hMLH1 interferes with normal, endogenous yMMR/bMMR, resulting in enhanced mutation rates (Shimodaira et al, 1998; Quaresima et al, 2003). Several mutations in hMLH1 abolish the capacity of the hMLH1-variant to interfere with yMMR/bMMR, thus restoring normal mutation rates (Shimodaira et al, 1998; Quaresima et al, 2003; Takahashi et al, 2007). Generally, in vitro assays concur with findings in such studies (Takahashi et al, 2007). Furthermore, there are alternative/complementary strategies for assessing hMLH1 function in yeast. The N-terminus of MLH1 contains the highly conserved ATPase domain, allowing analogous variant hMLH1 mutations to be introduced into yMLH1 (Shcherbakova and Kunkel, 1999; Hoffmann et al, 2003). As this method is restricted to evolutionarily conserved N-terminus residues, hybrid mammal-yeast MLH1 have been generated to assess MMR function of hMLH1 variants in budding yeast (Polaczek et al, 1998).
###end p 8
###begin p 9
###xml 399 413 399 413 <italic>hMLH1-Gly67Arg</italic>
Here, we describe the functional analysis of a variant hMLH1 protein following our description of a Lynch syndrome kindred with a unique collection of tumours rarely seen in this condition. Functional analysis of hMLH1 suggests that the mutation of p.Gly67Glu perturbs the protein's ability to prevent the accumulation of mutations. This loss-of-function is similar to a previously analysed allele, hMLH1-Gly67Arg, which has been described in Lynch syndrome families. Our observations suggest that the loss-of-function of hMLH1 is not sufficient to predict the type of tumours. We suggest that other genetic modifiers may be present to explain the phenotype and/or that the function of hMLH1 may differ from one cell type to another.
###end p 9
###begin title 10
Materials and methods
###end title 10
###begin title 11
Plasmids pRS315
###end title 11
###begin p 12
###xml 27 32 27 32 <italic>hMLH1</italic>
###xml 37 47 37 47 <italic>hMLH1-G67R</italic>
###xml 455 458 455 458 <italic>MAT</italic>
###xml 458 459 458 459 <bold>a</bold>
###xml 461 498 461 498 <italic>his4-R1, leu2-R1, ade1-1, lys2&#8759;InsE-A</italic>
###xml 498 500 498 500 <italic>14</italic>
###xml 498 500 498 500 <sub><italic>14</italic></sub>
###xml 500 512 500 512 <italic>CAN1, ura3-N</italic>
###xml 871 876 871 876 <italic>et al</italic>
###xml 862 882 862 882 <xref ref-type="other" rid="bib13">Hoffmann <italic>et al</italic>, 2003</xref>
###xml 421 426 <span type="species:ncbi:4932">yeast</span>
###xml 794 799 <span type="species:ncbi:4932">yeast</span>
Plasmids pRS315 containing hMLH1 and hMLH1-G67R were kindly provided by Dr Shimodaira. The hMLH1-G67E and yMLH1-G64R mutations were generated using the Quick Change Site-directed Mutagenesis kit from Stratagene (La Jolla, CA, USA) using primers hMLHG67E for 5'-AGGGAGGCCTGAAGTTGATTCAGATCCAAGACAATGGCA CCGAGATCAGG-3' and hMLHG67Erev for 5'-GGGGTTTGCTCAGAGGCTGCAGAAATGCATCAAGC-3'. Plasmids were introduced into the haploid yeast strain Y39 (Y55 background, MATa, his4-R1, leu2-R1, ade1-1, lys2∷InsE-A14CAN1, ura3-N). Plasmid yMLH1-G64E was generated as above using plasmid yMLH1-G64R as a template and primers yMLHG64E for 5'-CAAATAACAGATAACGGATCTGAAATTAATAAAGCAGACCTGCCA-3' and yMLHG64Erev for 5'-TGGCAGGTCTGCTTTATTAATTTCAGATCCGTTATCTGTTATTTG-3'. The yMLH1-G64E mutation was integrated into the yeast genome by two-step gene replacement, as described previously (Hoffmann et al, 2003).
###end p 12
###begin title 13
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
Yeast media
###end title 13
###begin p 14
###xml 59 64 59 64 <italic>et al</italic>
###xml 50 71 50 71 <xref ref-type="other" rid="bib13">Hoffmann <italic>et al</italic>, 2003)</xref>
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
Yeast media were generated and used according to (Hoffmann et al, 2003).
###end p 14
###begin title 15
Fluctuation tests
###end title 15
###begin p 16
###xml 67 88 67 88 <xref ref-type="other" rid="bib19">Lea and Coulson, 1949</xref>
###xml 90 115 90 115 <xref ref-type="other" rid="bib31">Reenan and Kolodner, 1992</xref>
Fluctuation tests were carried out using the method of the median (Lea and Coulson, 1949; Reenan and Kolodner, 1992). We assessed 11 colonies from three independent transformants for each mutation.
###end p 16
###begin title 17
Immunoblotting
###end title 17
###begin p 18
###xml 100 101 100 101 <sup>7</sup>
###xml 145 147 145 146 <italic>&#956;</italic>
###xml 327 329 326 327 <italic>&#956;</italic>
###xml 359 360 357 358 <sc>M</sc>
###xml 405 409 403 404 <italic>&#946;</italic>
###xml 723 728 <span type="species:ncbi:10090">mouse</span>
###xml 822 833 <span type="species:ncbi:3704">horseradish</span>
###xml 880 885 <span type="species:ncbi:10090">mouse</span>
Total protein was extracted from the transformants expressing the hMLH1variants. A total of 3.5 x 107 cells were disrupted by glass beads in 200 mul 20% trichloroacetic acid (TCA) in a FastPrep cell disrupter (Thermo Savant, Breda, Netherlands). The glass beads were removed and the precipitated protein was resuspended in 100 mul sample loading buffer (250 mM Tris-HCl, pH 8.0, 5% glycerol, 0.4% SDS, 1% beta-mercaptoethanol, 0.02% Bromophenol Blue). Equal amounts of protein, as determined by the Bradford assay, were separated by SDS polyacrylamide gel electrophoresis (6%). Proteins were electrophoretically transferred onto a nitrocellulose membrane (Amersham Biosciences, Amersham, UK), which was probed first with a mouse hMLH1 antibody (1 : 500, G168-15, BD Biosciences, Erembodegem, Belgium), and secondly with a horseradish peroxidase-conjugated antibody raised against mouse IgG (1 : 3000, Dako, Glostrup, Denmark). Expressed protein was detected by chemiluminescence (Western Lightning Chemiluminescence Reagent, PerkinElmer, Waltham, MA, USA).
###end p 18
###begin title 19
Results
###end title 19
###begin title 20
###xml 44 61 44 61 <italic>hMLH1-p. Gly76Glu</italic>
Genetic analysis and tumour spectrum of the hMLH1-p. Gly76Glu variant: a case study
###end title 20
###begin p 21
###xml 499 504 499 504 <italic>et al</italic>
###xml 493 510 493 510 <xref ref-type="other" rid="bib42">Vasen <italic>et al</italic>, 1999</xref>
A Caucasian male was seen in clinic with a history of male breast cancer and leiomyosarcoma of the thigh (presenting concurrently in his third decade), colon cancer (presented in his fourth decade) and prostate cancer (presented in his fifth decade). There were colorectal cancers with the age of onset in the fourth decade in his paternal grandfather and two paternal uncles. This family history is consistent with the revised Amsterdam criteria for the clinical diagnosis of Lynch syndrome (Vasen et al, 1999). His father had oesophageal cancer at the age of 47 years. Other unusual tumours in carriers of the variant included cervical adenosquamous carcinoma, oligodendroglioma and prostate cancer.
###end p 21
###begin p 22
###xml 68 72 68 72 <italic>TP53</italic>
###xml 172 177 172 177 <italic>BRCA1</italic>
###xml 182 187 182 187 <italic>BRCA2</italic>
Initial genetic screening for mutations (by full sequencing) in the TP53 gene responsible for the Li-Fraumeni syndrome was negative. The breast cancer susceptibility genes BRCA1 and BRCA2 also did not harbour any mutations as screened by dHPLC (denaturing high-performance liquid chromatography) and MLPA (multiplex ligation-dependent probe amplification).
###end p 22
###begin p 23
###xml 191 196 191 196 <italic>hMLH1</italic>
Several of the tumours in this family including the proband's sarcoma showed microsatellite instability. Molecular analysis of the proband's germline DNA identified a missense variant in the hMLH1 gene in exon 2 at nucleotide position 200 (c.200 G>A). This results in an amino-acid substitution from glycine to glutamic acid (Gly67Glu/G67E). The Gly67Glu mutation segregates with cancer predisposition across the pedigree.
###end p 23
###begin title 24
###xml 49 54 <span type="species:ncbi:4932">yeast</span>
Expression of hMLH1-G67E does not interfere with yeast MMR
###end title 24
###begin p 25
To determine whether hMLH1-p.Gly67Glu (denoted hMLH1-G67E henceforth) is functional in MMR, we used two different approaches.
###end p 25
###begin p 26
###xml 353 361 353 361 <xref ref-type="fig" rid="fig1">Figure 1</xref>
###xml 374 379 374 379 <italic>et al</italic>
###xml 363 385 363 385 <xref ref-type="other" rid="bib35">Shimodaira <italic>et al</italic>, 1998</xref>
###xml 468 473 468 473 <italic>hMLH1</italic>
###xml 475 485 475 485 <italic>hMLH1-G67R</italic>
###xml 489 499 489 499 <italic>hMLH1-G67E</italic>
###xml 542 546 542 546 <italic>CAN1</italic>
###xml 580 592 580 592 <italic>lys2::InsE-A</italic>
###xml 592 594 592 594 <italic>14</italic>
###xml 592 594 592 594 <sub><italic>14</italic></sub>
###xml 596 600 596 600 <italic>CAN1</italic>
###xml 710 714 710 714 <italic>CAN1</italic>
###xml 836 847 836 847 <italic>lys2&#8759;InsE-A</italic>
###xml 847 849 847 849 <italic>14</italic>
###xml 847 849 847 849 <sub><italic>14</italic></sub>
###xml 936 940 936 940 <italic>LYS2</italic>
###xml 947 952 947 952 <italic>et al</italic>
###xml 942 958 942 958 <xref ref-type="other" rid="bib38">Tran <italic>et al</italic>, 1997</xref>
###xml 985 989 985 989 <italic>LYS2</italic>
###xml 994 999 994 995 <italic>&#945;</italic>
###xml 1196 1207 1192 1203 <italic>lys2&#8759;InsE-A</italic>
###xml 1207 1209 1203 1205 <italic>14</italic>
###xml 1207 1209 1203 1205 <sub><italic>14</italic></sub>
###xml 1211 1220 1207 1216 <xref ref-type="fig" rid="fig1">Figure 1A</xref>
###xml 1260 1265 1256 1261 <italic>hMLH1</italic>
###xml 1310 1321 1306 1317 <italic>lys2&#8759;InsE-A</italic>
###xml 1321 1323 1317 1319 <italic>14</italic>
###xml 1321 1323 1317 1319 <sub><italic>14</italic></sub>
###xml 1418 1428 1414 1424 <italic>hMLH1-G67R</italic>
###xml 1560 1570 1556 1566 <italic>hMLH1-G67E</italic>
###xml 1597 1607 1593 1603 <italic>hMLH1-G67R</italic>
###xml 1680 1689 1676 1685 <xref ref-type="fig" rid="fig1">Figure 1A</xref>
###xml 1740 1750 1736 1746 <italic>hMLH1-G67E</italic>
###xml 1953 1957 1949 1953 <italic>CAN1</italic>
###xml 1962 1973 1958 1969 <italic>lys2&#8759;InsE-A</italic>
###xml 1973 1975 1969 1971 <italic>14</italic>
###xml 1973 1975 1969 1971 <sub><italic>14</italic></sub>
###xml 1993 1998 1989 1994 <italic>hMLH1</italic>
###xml 2076 2087 2072 2083 <italic>lys2&#8759;InsE-A</italic>
###xml 2087 2089 2083 2085 <italic>14</italic>
###xml 2087 2089 2083 2085 <sub><italic>14</italic></sub>
###xml 2094 2098 2090 2094 <italic>CAN1</italic>
###xml 2122 2132 2118 2128 <italic>hMLH1-G67R</italic>
###xml 2182 2193 2178 2189 <italic>lys2&#8759;InsE-A</italic>
###xml 2193 2195 2189 2191 <italic>14</italic>
###xml 2193 2195 2189 2191 <sub><italic>14</italic></sub>
###xml 2213 2217 2209 2213 <italic>CAN1</italic>
###xml 2275 2282 2271 2278 <xref rid="tbl1" ref-type="table">Table 1</xref>
###xml 2285 2295 2281 2291 <italic>hMLH1-G67E</italic>
###xml 2325 2335 2321 2331 <italic>hMLH1-G67R</italic>
###xml 2404 2411 2400 2407 <xref rid="tbl1" ref-type="table">Table 1</xref>
###xml 2430 2440 2426 2436 <italic>hMLH1-G67E</italic>
###xml 2485 2495 2481 2491 <italic>hMLH1-G67R</italic>
###xml 72 77 <span type="species:ncbi:9606">human</span>
###xml 133 138 <span type="species:ncbi:4932">yeast</span>
###xml 328 333 <span type="species:ncbi:4932">yeast</span>
###xml 411 416 <span type="species:ncbi:4932">yeast</span>
###xml 1840 1845 <span type="species:ncbi:4932">yeast</span>
We took the advantage of the findings that the expression of functional human MLH1 (hMLH1) interferes with normal MMR in the budding yeast, whereas several point mutants associated with Lynch syndrome fail to do so. For example, hMLH1-p.Gly67Arg (G67R), known to occur in HNPCC families, shows reduced ability to interfere with yeast MMR in this assay (Figure 1; Shimodaira et al, 1998). We transformed budding yeast (Y39) with vector only (pRS315), vector containing hMLH1, hMLH1-G67R or hMLH1-G67E and assessed the forward mutation rate of CAN1 as well as the reversion rate of lys2::InsE-A14. CAN1 encodes an arginine permease that renders cells sensitive to the arginine analogue, canavanine. Mutations in CAN1 include base substitutions as well as insertions and deletions, which cause cells to become resistant to canavanine. The lys2∷InsE-A14 contains a homopolymeric run of 14 adenines, which causes a +1 frameshift mutation in LYS2 (Tran et al, 1997). Reversion reconstitutes LYS2, an alpha-aminoadipate reductase that allows cells to synthesise lysine. Qualitative assessment of four independent transformants shows that the 'vector only' has no discernible effect on mutation rates of lys2∷InsE-A14 (Figure 1A). In contrast, introduction of 'vector+hMLH1' causes an increase in the mutation rate of lys2∷InsE-A14, consistent with aberrant yMMR. Cells transformed with the previously characterized mutation, hMLH1-G67R, do not display an increased mutator phenotype, although some of the transformants do show a stochastic increase (data not shown). hMLH1-G67E behaved very similarly to hMLH1-G67R in that the majority of transformants did not show a mutator phenotype (Figure 1A and data not shown). These observations show that hMLH1-G67E displays a strongly reduced capacity for interfering with normal MMR function in budding yeast. We also quantified the mutation rates using the method of the median (see Materials and Methods) for both CAN1 and lys2∷InsE-A14. Introduction of hMLH1 causes a 18 700-fold and 5.1-fold increase in the mutation rate estimates of lys2∷InsE-A14 and CAN1, respectively, whereas hMLH1-G67R did not enhance the mutation rates (1.2-fold for lys2∷InsE-A14 and 0.6-fold for CAN1 change in mutation rates as compared with 'vector only'; Table 1). hMLH1-G67E shows a similar phenotype to hMLH1-G67R, with 1.9-fold and 1.1-fold difference compared with 'vector only' (Table 1), suggesting that hMLH1-G67E has a similar loss-of-function phenotype as hMLH1-G67R in this assay.
###end p 26
###begin p 27
###xml 82 87 82 87 <italic>et al</italic>
###xml 71 93 71 93 <xref ref-type="other" rid="bib35">Shimodaira <italic>et al</italic>, 1998</xref>
###xml 219 228 219 228 <xref ref-type="fig" rid="fig1">Figure 1B</xref>
###xml 58 63 <span type="species:ncbi:4932">yeast</span>
###xml 445 450 <span type="species:ncbi:4932">yeast</span>
The hMLH1 and hMLH1-G67R proteins are expressed stably in yeast cells (Shimodaira et al, 1998). To determine whether this is also the case for hMLH1-G67E, we carried out western blot analyses on the four transformants (Figure 1B). Protein extracts from cells containing hMLH1, hMLH1-G67R and the four independent transformants of hMLH1-G67E, but not vector only, showed the diagnostic 80 kD band. Thus, hMLH1-G67E is stably expressed in budding yeast cells, but shows reduced ability to interfere with normal MMR functions.
###end p 27
###begin title 28
yMLH1-G64R confers increased mutation rates
###end title 28
###begin p 29
###xml 79 83 79 83 <italic>MLH1</italic>
###xml 193 203 193 203 <italic>hMLH1-G67R</italic>
###xml 320 330 320 330 <italic>yMLH1-G64R</italic>
###xml 332 361 332 361 <xref ref-type="other" rid="bib34">Shcherbakova and Kunkel, 1999</xref>
###xml 433 443 433 443 <italic>yMLH1-G64E</italic>
###xml 478 485 478 485 <xref rid="tbl2" ref-type="table">Table 2</xref>
###xml 501 505 501 505 <italic>MLH1</italic>
###xml 574 578 574 578 <italic>CAN1</italic>
###xml 583 594 583 594 <italic>lys2&#8759;InsE-A</italic>
###xml 594 596 594 596 <italic>14</italic>
###xml 594 596 594 596 <sub><italic>14</italic></sub>
###xml 652 662 652 662 <italic>yMLH1-G64R</italic>
###xml 772 782 772 782 <italic>yMLH1-G64E</italic>
###xml 806 816 806 816 <italic>yMLh1-G64R</italic>
###xml 11 16 <span type="species:ncbi:4932">yeast</span>
###xml 308 313 <span type="species:ncbi:4932">yeast</span>
###xml 420 425 <span type="species:ncbi:4932">yeast</span>
The second yeast assay we employed is based on the observation that eukaryotic MLH1 homologues are highly conserved in the N-terminal ATPase domain. Several Lynch syndrome mutations, including hMLH1-G67R, confer a loss-of-function phenotype for mutator activity when introduced into the analogous residue in yeast MLH1 (yMLH1-G64R; Shcherbakova and Kunkel, 1999). We introduced the G67E change directly into the budding yeast locus (yMLH1-G64E) and assessed the mutation rates (Table 2). Deletion of yMLH1 causes a 30-fold and 19 000-fold increase in the mutation rates for CAN1 and lys2∷InsE-A14, respectively, compared with the wild-type strain. The yMLH1-G64R mutant protein confers an intermediate phenotype, but nevertheless shows highly elevated mutation rates. The yMLH1-G64E mutation is similar to yMLh1-G64R, suggesting that changing the G64 residue in yMLH1 to either a positively charged arginine or a negatively charged glutamate confers similar inhibition of protein activity during MMR.
###end p 29
###begin title 30
Discussion
###end title 30
###begin p 31
###xml 332 338 332 338 <italic>hMLH1.</italic>
Characterising MMR gene alterations in Lynch syndrome families is important in clarifying risk and advising on management issues, such as cancer surveillance, treatment and prevention. Detailed study of a family with a tumour spectrum satisfying the Amsterdam criteria for Lynch syndrome has allowed us to characterise a variant in hMLH1. Interestingly, in addition to classic tumours, this family also exhibits a collection of atypical tumours. Functional analysis of this variant shows that it confers a loss-of-function mutator phenotype.
###end p 31
###begin p 32
###xml 4 26 4 26 <italic>p.Gly67Glu (p.Gly64Glu</italic>
###xml 120 138 120 138 <xref ref-type="other" rid="bib2">Ban and Yang, 1998</xref>
###xml 266 284 266 284 <xref ref-type="other" rid="bib2">Ban and Yang, 1998</xref>
###xml 290 295 290 295 <italic>et al</italic>
###xml 286 301 286 301 <xref ref-type="other" rid="bib1">Ban <italic>et al</italic>, 1999</xref>
###xml 408 413 408 413 <italic>et al</italic>
###xml 404 419 404 419 <xref ref-type="other" rid="bib1">Ban <italic>et al</italic>, 1999</xref>
###xml 564 569 564 565 <italic>&#945;</italic>
###xml 580 601 576 597 <xref ref-type="other" rid="bib39">Tran and Liskay, 2000</xref>
###xml 649 665 645 661 <italic>hMLH1-p.Gly67Glu</italic>
###xml 763 778 759 774 <italic>hMLH1-pGly67Arg</italic>
###xml 780 798 776 794 <xref ref-type="other" rid="bib2">Ban and Yang, 1998</xref>
###xml 1279 1289 1275 1285 <italic>hMLH1-G67E</italic>
###xml 1331 1341 1327 1337 <italic>hMLH1-G67R</italic>
###xml 30 35 <span type="species:ncbi:4932">yeast</span>
###xml 1029 1034 <span type="species:ncbi:4932">yeast</span>
###xml 1152 1157 <span type="species:ncbi:4932">yeast</span>
The p.Gly67Glu (p.Gly64Glu in yeast) mutation alters an amino-acid residue in the highly conserved N-terminus of hMLH1 (Ban and Yang, 1998). By analogy to the crystal structure of bacterial MutL, G67 is positioned on a loop, which is part of the ATP-binding pocket (Ban and Yang, 1998; Ban et al, 1999). ATP-binding induces conformational changes in the N-terminus that allows MutL monomers to dimerise (Ban et al, 1999), thus facilitating the interaction between hMLH1 and hPMS2. Moreover, cycles of ATP-binding and hydrolysis have been suggested to regulate MutLalpha activity (Tran and Liskay, 2000). Structure predictions would suggest that the hMLH1-p.Gly67Glu substitution alters the local conformation of the hMLH1 protein, analogous to that predicted for hMLH1-pGly67Arg (Ban and Yang, 1998). We tested this directly by comparing the G67E/G64E mutation to a previously characterised mutant in the same residue (G67R/G64R) in two functional assays. It is clear that expressing hMLH1-G67E does not appear to interfere with yeast MMR, which is not the case when normal hMLH1 is present. Furthermore, when the analogous substitution is made in the yeast protein, yMLH1-G64E, this protein does not sustain MMR fully and is as compromised as yMLH1-G64R. Thus, we conclude that hMLH1-G67E is a loss-of-function allele, similar to hMLH1-G67R.
###end p 32
###begin p 33
###xml 24 34 24 34 <italic>hMLH1-G67E</italic>
###xml 185 195 185 195 <italic>hMLH1-G67R</italic>
###xml 268 273 268 273 <italic>et al</italic>
###xml 259 279 259 279 <xref ref-type="other" rid="bib12">Herfarth <italic>et al</italic>, 1997</xref>
###xml 291 296 291 296 <italic>et al</italic>
###xml 281 302 281 302 <xref ref-type="other" rid="bib11">Heinimann <italic>et al</italic>, 1999</xref>
###xml 312 317 312 317 <italic>et al</italic>
###xml 304 323 304 323 <xref ref-type="other" rid="bib28">Plevov&#225; <italic>et al</italic>, 2004</xref>
###xml 343 353 343 353 <italic>hMLH1-G67E</italic>
###xml 450 455 450 455 <italic>et al</italic>
###xml 440 461 440 461 <xref ref-type="other" rid="bib3">Barnetson <italic>et al</italic>, 2008</xref>
###xml 594 605 594 605 <xref ref-type="other" rid="bib33">Scott, 2008</xref>
We have identified that hMLH1-G67E segregates with disease in the family reported and is associated with atypical cancers. This is in sharp contrast to reported kindreds harbouring the hMLH1-G67R mutation who only showed classical elements of Lynch syndrome (Herfarth et al, 1997; Heinimann et al, 1999; Plevova et al, 2004). Furthermore, the hMLH1-G67E mutation has not been reported in 1688 individuals studied in the general population (Barnetson et al, 2008), consistent with the mutation being pathogenic. Our observations suggest that alleles that modify the effect of the G67E mutation (Scott, 2008) may be present in this family to explain the unusual spectrum. Alternatively, there may be functions of hMLH1 that are not assessed simply by determining whether the resulting change causes a mutator phenotype.
###end p 33
###begin p 34
Because of the rarity of tumours in our Lynch syndrome family, this poses significant clinical management issues regarding recommendations on screening and treatment. Identification of more families with this pathogenic mutation could shed light on the mechanism for carcinogenesis in our kindred.
###end p 34
###begin p 35
###xml 64 69 64 69 <italic>hMLH1</italic>
###xml 74 84 74 84 <italic>hMLH1-G67R</italic>
We thank Dr Shimodaira for providing us the plasmids containing hMLH1 and hMLH1-G67R. We are grateful to Drs Stewart J Payne, Sam Fisher, Ian Frayling, Rebecca Barnetson and Ann Barrett for helpful discussion during the preparation of the manuscript.
###end p 35
###begin p 36
###xml 0 20 0 20 <bold>Conflict of interest</bold>
Conflict of interest
###end p 36
###begin p 37
We declare the authors do not have any competing interests.
###end p 37
###begin p 38
Funding: MC is funded by an MRC studentship and EH is funded by a Royal Society Dorothy Hodgkin fellowship. Work in the Hoffmann Laboratory was funded by a project grant from the Cancer Research, UK.
###end p 38
###begin p 39
Work in the Yu Laboratory was funded by the MRC.
###end p 39
###begin p 40
RE is supported by the Institute of Cancer Research and by the NHS funding to the NIHR Biomedical Research Centre.
###end p 40
###begin article-title 41
Transformation of MutL by ATP binding and hydrolysis: a switch in DNA mismatch repair
###end article-title 41
###begin article-title 42
Crystal structure and ATPase activity of MutL: Implications for DNA repair and mutagenesis
###end article-title 42
###begin article-title 43
Classification of ambiguous mutations in DNA mismatch repair genes identified in a population-based study of colorectal cancer
###end article-title 43
###begin article-title 44
###xml 2 7 <span type="species:ncbi:9606">human</span>
A human cell-based assay to evaluate the effects of alterations in the MLH1 mismatch repair gene
###end article-title 44
###begin article-title 45
Transient mismatch repair gene transfection for functional analysis of genetic hMLH1 and hMSH2 variants
###end article-title 45
###begin article-title 46
###xml 51 56 51 56 <italic>hMLH1</italic>
Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer
###end article-title 46
###begin article-title 47
###xml 10 15 <span type="species:ncbi:9606">human</span>
A defined human system that supports bidirectional mismatch-provoked excision
###end article-title 47
###begin article-title 48
###xml 31 35 31 35 <italic>MSH2</italic>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer
###end article-title 48
###begin article-title 49
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human MRE11 is inactivated in mismatch repair-deficient cancers
###end article-title 49
###begin article-title 50
HNPCC mutations in hMSH2 result in reduced hMSH2-hMSH6 molecular switch functions
###end article-title 50
###begin article-title 51
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Influence of selection criteria on mutation detection in patients with hereditary nonpolyposis colorectal cancer
###end article-title 51
###begin article-title 52
Mutations in MLH1 are more frequent than in MSH2 in sporadic colorectal cancers with microsatellite instability
###end article-title 52
###begin article-title 53
###xml 0 4 0 4 <italic>MLH1</italic>
###xml 58 82 58 82 <italic>Saccharomyces cerevisiae</italic>
###xml 58 82 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
MLH1 mutations differentially affect meiotic functions in Saccharomyces cerevisiae
###end article-title 53
###begin article-title 54
APC mutations in colorectal tumors with mismatch repair deficiency
###end article-title 54
###begin article-title 55
###xml 41 46 <span type="species:ncbi:9606">human</span>
Endonucleolytic function of MutLalpha in human mismatch repair
###end article-title 55
###begin article-title 56
Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome
###end article-title 56
###begin article-title 57
Chk1 frameshift mutation in sporadic and hereditary non-polyposis colorectal cancers with microsatellite instability
###end article-title 57
###begin article-title 58
PTEN1 is frequently mutated in primary endometrial carcinomas
###end article-title 58
###begin article-title 59
The distribution of the numbers of mutants in bacterial populations
###end article-title 59
###begin article-title 60
DNA mismatch repair and cancer
###end article-title 60
###begin article-title 61
Hereditary colorectal cancer
###end article-title 61
###begin article-title 62
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability
###end article-title 62
###begin article-title 63
Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability
###end article-title 63
###begin article-title 64
Mechanisms in eukaryotic mismatch repair
###end article-title 64
###begin article-title 65
Mutations of two PMS homologues in hereditary nonpolyposis colon cancer
###end article-title 65
###begin article-title 66
Functional analysis of MLH1 mutations linked to hereditary nonpolyposis colon cancer
###end article-title 66
###begin article-title 67
###xml 14 18 14 18 <italic>mutL</italic>
Mutation of a mutL homolog in hereditary colon cancer
###end article-title 67
###begin article-title 68
Immunohistochemical detection of the hMLH1 and hMSH2 proteins in hereditary non-polyposis colon cancer and sporadic colon cancer
###end article-title 68
###begin article-title 69
###xml 68 92 68 92 <italic>Saccharomyces cerevisiae</italic>
###xml 68 92 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Functional genetic tests of DNA mismatch repair protein activity in Saccharomyces cerevisiae
###end article-title 69
###begin article-title 70
###xml 100 107 100 107 <italic>in vivo</italic>
###xml 112 120 112 120 <italic>in vitro</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 69 85 <span type="species:ncbi:562">Escherichia coli</span>
Human mismatch-repair protein MutL homologue 1 (MLH1) interacts with Escherichia coli MutL and MutS in vivo and in vitro: a simple genetic system to assay MLH1 function
###end article-title 70
###begin article-title 71
###xml 47 71 47 71 <italic>Saccharomyces cerevisiae</italic>
###xml 71 75 71 75 <italic>MSH1</italic>
###xml 80 84 80 84 <italic>MSH2</italic>
Characterisation of insertion mutations in the Saccharomyces cerevisiaeMSH1 and MSH2 genes: evidence for separate mitochondrial and nuclear functions
###end article-title 71
###begin article-title 72
###xml 46 51 <span type="species:ncbi:9606">human</span>
The DNA repair gene MBD4 (MED1) is mutated in human carcinomas with microsatellite instability
###end article-title 72
###begin article-title 73
Modifier Genes and HNPCC: variable phenotypic expression in HNPCC and the search for modifier genes
###end article-title 73
###begin article-title 74
###xml 32 36 32 36 <italic>MLH1</italic>
###xml 78 82 78 82 <italic>mlh1</italic>
Mutator phenotypes conferred by MLH1 overexpression and by heterozygosity for mlh1 mutations
###end article-title 74
###begin article-title 75
###xml 47 71 47 71 <italic>Saccharomyces cerevisiae</italic>
###xml 23 28 <span type="species:ncbi:9606">human</span>
###xml 47 71 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Functional analysis of human MLH1 mutations in Saccharomyces cerevisiae
###end article-title 75
###begin article-title 76
###xml 59 67 59 67 <italic>in vitro</italic>
###xml 23 28 <span type="species:ncbi:9606">human</span>
###xml 49 54 <span type="species:ncbi:4932">yeast</span>
Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays
###end article-title 76
###begin article-title 77
Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies
###end article-title 77
###begin article-title 78
###xml 90 95 <span type="species:ncbi:4932">yeast</span>
Hypermutability of homonucleotide runs in mismatch repair and DNA polymerase proofreading yeast mutants
###end article-title 78
###begin article-title 79
###xml 54 78 54 78 <italic>Saccharomyces cerevisiae</italic>
###xml 54 78 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Functional studies on the candidate ATPase domains of Saccharomyces cerevisiae MutLa
###end article-title 79
###begin article-title 80
###xml 74 79 <span type="species:ncbi:9606">human</span>
Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system
###end article-title 80
###begin article-title 81
Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability
###end article-title 81
###begin article-title 82
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC
###end article-title 82
###begin article-title 83
Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas
###end article-title 83
###begin p 84
###xml 1 2 1 2 <bold>A</bold>
###xml 78 83 78 83 <italic>hMLH1</italic>
###xml 85 95 85 95 <italic>hMLH1-G67R</italic>
###xml 99 109 99 109 <italic>hMLH1-G67E</italic>
###xml 152 156 152 156 <italic>CAN1</italic>
###xml 190 202 190 202 <italic>lys2::InsE-A</italic>
###xml 202 204 202 204 <italic>14</italic>
###xml 202 204 202 204 <sub><italic>14</italic></sub>
###xml 315 316 315 316 <bold>B</bold>
###xml 4 9 <span type="species:ncbi:4932">Yeast</span>
###xml 268 273 <span type="species:ncbi:4932">yeast</span>
###xml 390 395 <span type="species:ncbi:4932">Yeast</span>
(A) Yeast cells were transformed with vector only (pRS315), vector containing hMLH1, hMLH1-G67R or hMLH1-G67E and assessed the forward mutation rate of CAN1 as well as the reversion rate of lys2::InsE-A14. The hMLH1-G67E mutant shows reduced ability to interfere with yeast MMR similar to the hMLH1-G67R mutation. (B) Western blot analyses of the four separate transformants of hMLH1-G67E. Yeast cells stably express wild-type hMLH1 protein as well as the hMLH1-G67R and the hMLH1-G67E mutants.
###end p 84
###begin p 85
###xml 6 16 6 16 <italic>hMLH1-G67E</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 48 53 <span type="species:ncbi:4932">yeast</span>
Human hMLH1-G67E mutant does not interfere with yeast MMR
###end p 85
###begin p 86
MMR=mismatch repair.
###end p 86
###begin p 87
###xml 31 36 <span type="species:ncbi:4932">yeast</span>
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 166 171 <span type="species:ncbi:4932">yeast</span>
Mutation rates are assessed in yeast strains expressing the various forms of human MLH1 proteins. Only wild-type hMLH1 was capable of interfering with the endogenous yeast MMR to increase mutation rates.
###end p 87
###begin p 88
Mutation rate estimated as mutation/cell/generation.
###end p 88
###begin p 89
###xml 29 39 29 39 <italic>yMLH1-G64E</italic>
###xml 23 28 <span type="species:ncbi:4932">yeast</span>
Mutation rates for the yeast yMLH1-G64E mutant are elevated
###end p 89
###begin p 90
WT=wild type.
###end p 90
###begin p 91
###xml 57 61 57 61 <italic>mlh1</italic>
###xml 101 105 101 105 <italic>mlh1</italic>
###xml 119 123 119 123 <italic>mlh1</italic>
###xml 207 211 207 211 <italic>G64R</italic>
###xml 215 219 215 219 <italic>G64E</italic>
###xml 3 8 <span type="species:ncbi:4932">yeast</span>
###xml 33 38 <span type="species:ncbi:4932">yeast</span>
###xml 95 100 <span type="species:ncbi:4932">yeast</span>
WT yeast cells are compared with yeast cells deleted for mlh1 or expressing mutant versions of yeast mlh1. Deletion of mlh1 greatly elevated mutation rates as expected. The single-point mutation of ymlh1 of G64R or G64E also increased the mutation rates significantly.
###end p 91
###begin p 92
Mutation rate estimated as mutation/cell/generation.
###end p 92

